| Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease. | |
| | |
MedLine Citation:
|
PMID: 11401125 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: This study aimed to elucidate whether an antibody against oxidized low density lipoprotein (anti-Ox-LDL) could predict short-term coronary artery atherosclerotic lesion progression. BACKGROUND: It is still controversial whether higher levels of the anti-Ox-LDL titer are associated with atherosclerotic coronary artery disease. METHODS: In 52 patients undergoing coronary angioplasty and six-month follow-up angiography, we performed quantitative coronary angiographic analysis of a lesion on a branch away from the intervention site vessel and assessed lesion progression or regression using the Progression-Regression score calculated as the baseline minimal lumen diameter minus the follow-up minimal lumen diameter. The serum anti-Ox-LDL titer was measured using an enzyme-linked immunosorbent assay method just before the initial angiography in all patients. RESULTS: The anti-Ox-LDL titer was 16.6+/-1.5 AcU/ml in the progression group (Progression-Regression score >0.15 mm; n = 20), which was significantly higher (p < 0.001) than the value of 9.5+/-1.2 in the regression group (< or =-0.15 mm; n = 14) and also higher (p < 0.01) than the value of 11.4+/-1.3 in the no-change group (-0.15 to 0.15 mm; n = 18). The Progression-Regression score was correlated with the antibody titer in all patients (r = 0.56, p < 0.001). Multiple regression analysis showed that the Progression-Regression score was independently correlated with the antibody titer (r = 0.44, p < 0.01) as well as lipoprotein (a) (r = 0.33, p < 0.05). CONCLUSIONS: Anti-Ox-LDL may be an independent predictor of coronary atherosclerotic lesion progression in the short term. |
| | |
Authors:
|
T Inoue; T Uchida; H Kamishirado; K Takayanagi; S Morooka |
Related Documents
:
|
19080725 - Should we treat all patients with coronary heart disease or the equivalent with statins? 17077375 - Statin therapy and risks for death and hospitalization in chronic heart failure. 6386225 - Thirty-five years of progress in cardiovascular research. 15944615 - Cardiovascular risk prevention in peripheral artery disease. 12515735 - Aspirin alters the cardioprotective effects of the factor xiii val34leu polymorphism. 16885425 - Motor recovery as assessed with isometric finger movements and perfusion magnetic reson... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 37 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 2001 Jun |
Date Detail:
|
Created Date: 2001-06-12 Completed Date: 2001-08-09 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 1871-6 Citation Subset: AIM; IM |
Affiliation:
|
Department of Cardiology, Koshigaya Hospital, Dokkyo University School of Medicine, Saitama, Japan. inouet@dokkyomed.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies
/
blood* Coronary Artery Disease / blood, metabolism*, radiography* Disease Progression Female Humans Lipoproteins, LDL* / immunology*, metabolism* Male Middle Aged Oxidation-Reduction Predictive Value of Tests Prognosis Remission, Spontaneous |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies; 0/Lipoproteins, LDL |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Plaque distribution and vascular remodeling of ruptured and nonruptured coronary plaques in the same...
Next Document: Percutaneous and surgical interventions for in-stent restenosis: long-term outcomes and effect of di...